Clene Inc. (CLNN)Consumer Defensive | Packaged Foods | Salt Lake City, United States | NasdaqCM
3.31 USD
0.00
(-0.151%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:26 a.m. EDT
The investment case for Clene Inc. is currently broken by a catastrophic collapse in business value and a market that has priced in further ruin. Fundamentally, the company is a value trap: it trades at a negative book value, generates massive free cash flow losses, and boasts a negative operating margin of nearly 60%. While the company recently secured a potential FDA fast-track for its ALS drug, the stock has already lost over 95% of its value since 2018, suggesting the market views this as insufficient to reverse the structural decline. The recent price action confirms this pessimism, with the stock trading well below its 50-day and 200-day moving averages, indicating persistent selling pressure. Compounding the distress, the options market is screaming for a crash; the sheer volume of put options versus calls suggests investors are betting on a rapid descent to the $2.50 floor rather than a recovery. With no dividend to provide income and a balance sheet that is effectively insolvent relative to its operations, there is no margin of safety here. The stock is a speculative biotech gamble with no earnings path, making it unsuitable for any rational capital allocation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.144193 |
| MSTL | 0.157682 |
| AutoETS | 0.161911 |
| AutoARIMA | 0.322660 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.946 |
| Excess Kurtosis | 0.01 |
| Attribute | Value |
|---|---|
| Sector | Consumer Defensive |
| Revenue per Share | 0.017 |
| Market Cap | 46,977,208 |
| Forward P/E | -1.35 |
| Beta | 0.92 |
| Previous Name | Clene Nanomedicine Inc. |
| Website | https://clene.com |
As of Oct. 10, 2026, 7:26 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts expiring in October 2026 compared to negligible call volume. This creates a distinct 'bear put' skew where the market is pricing in a significant drop to the $2.50 strike level within a month, while long-dated calls show minimal interest despite some activity at the $5.00 strike.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5987879 |
| Address1 | 6,550 South Millrock Drive |
| Address2 | Suite G50 |
| All Time High | 356.4 |
| All Time Low | 2.28 |
| Ask | 3.33 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 91,540 |
| Average Daily Volume3 Month | 101,371 |
| Average Volume | 101,371 |
| Average Volume10Days | 91,540 |
| Beta | 0.919 |
| Bid | 3.22 |
| Bid Size | 1 |
| Book Value | -1.939 |
| City | Salt Lake City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.305 |
| Current Ratio | 3.074 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.439 |
| Day Low | 3.2 |
| Display Name | Clene |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,088,200 |
| Earnings Timestamp Start | 1,755,088,200 |
| Ebitda | -19,118,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.884 |
| Enterprise To Revenue | 279.885 |
| Enterprise Value | 55,137,336 |
| Eps Current Year | -2.62 |
| Eps Forward | -2.44 |
| Eps Trailing Twelve Months | -3.38 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.1566 |
| Fifty Day Average Change | -0.85159993 |
| Fifty Day Average Change Percent | -0.20487897 |
| Fifty Two Week Change Percent | -59.87879 |
| Fifty Two Week High | 13.5 |
| Fifty Two Week High Change | -10.195 |
| Fifty Two Week High Change Percent | -0.7551852 |
| Fifty Two Week Low | 3.2 |
| Fifty Two Week Low Change | 0.10500002 |
| Fifty Two Week Low Change Percent | 0.032812506 |
| Fifty Two Week Range | 3.2 - 13.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,539,869,400,000 |
| Float Shares | 10,530,127 |
| Forward Eps | -2.44 |
| Forward P E | -1.3545082 |
| Free Cashflow | -9,874,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 76 |
| Fullday Change | -0.06999993 |
| Fullday Change Percent | -2.1148016 |
| Fullday Price | 3.305 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.70051 |
| Gross Profits | 138,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16543 |
| Held Percent Institutions | 0.20524 |
| Implied Shares Outstanding | 14,213,981 |
| Industry | Packaged Foods |
| Industry Disp | Packaged Foods |
| Industry Key | packaged-foods |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,720,656,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah. |
| Long Name | Clene Inc. |
| Market | us_market |
| Market Cap | 46,977,208 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_339429732 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | -39,518,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 60,977,978 |
| Number Of Analyst Opinions | 5 |
| Open | 3.25 |
| Operating Cashflow | -15,907,000 |
| Operating Margins | -59.41111 |
| Payout Ratio | 0.0 |
| Phone | 801 676 9695 |
| Prev Name | Clene Nanomedicine Inc. |
| Previous Close | 3.31 |
| Price Eps Current Year | -1.2614504 |
| Price Hint | 4 |
| Price To Book | -1.7044868 |
| Price To Sales Trailing12 Months | 238.46298 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.237 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.004999876 |
| Regular Market Change Percent | -0.15105365 |
| Regular Market Day High | 3.439 |
| Regular Market Day Low | 3.2 |
| Regular Market Day Range | 3.2 - 3.439 |
| Regular Market Open | 3.25 |
| Regular Market Previous Close | 3.31 |
| Regular Market Price | 3.305 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 134,019 |
| Return On Assets | -0.56876 |
| Revenue Growth | 2.333 |
| Revenue Per Share | 0.017 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Consumer Defensive |
| Sector Disp | Consumer Defensive |
| Sector Key | consumer-defensive |
| Shares Outstanding | 14,213,981 |
| Shares Percent Shares Out | 0.062 |
| Shares Short | 880,688 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 965,618 |
| Short Name | Clene Inc. |
| Short Percent Of Float | 0.0801 |
| Short Ratio | 6.15 |
| Source Interval | 15 |
| State | UT |
| Symbol | CLNN |
| Target High Price | 50.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 32.2 |
| Target Median Price | 30.0 |
| Total Cash | 9,671,000 |
| Total Cash Per Share | 0.753 |
| Total Debt | 22,344,000 |
| Total Revenue | 197,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.30755 |
| Two Hundred Day Average Change | -2.00255 |
| Two Hundred Day Average Change Percent | -0.37730214 |
| Type Disp | Equity |
| Volume | 134,019 |
| Website | https://clene.com |
| Zip | 84,121 |